The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action

Pharmacology and Therapeutics

Volumn 126, Issue 2, 2010, Pages 173-185

  Wong, Erik H F ^a   Tarazi, Frank I ^b   Shahid, Mohammed ^c  

^a ASTRAZENECA   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Schering Plough Research Institute   (United Kingdom)

Author keywords

Antidepressant drugs; Antipsychotic drugs; Depression; Mood disorders; Multi target agents; Schizophrenia; Single target agents

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 4 [2 AMINO 4 (METHYLTHIO)BUTYRYLAMINO] 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; AMFEBUTAMONE; ASENAPINE; CLOZAPINE; FARAMPATOR; FLUOXETINE; ILOPERIDONE; KETAMINE; LITHIUM; LURASIDONE; MECAMYLAMINE; MINOCYCLINE; MIRTAZAPINE; OLANZAPINE; PALIPERIDONE; PAROXETINE; PERPHENAZINE; PINDOLOL; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; SAREDUTANT; SCOPOLAMINE; TAMOXIFEN; UNINDEXED DRUG; VABICASERIN; VALPROIC ACID; XANOMELINE; ZIPRASIDONE;

ALZHEIMER DISEASE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; BONE MARROW TOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; CONVULSION; DAYTIME SOMNOLENCE; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HAND TREMOR; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; METABOLIC DISORDER; MOOD DISORDER; MOTOR DYSFUNCTION; NAUSEA; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PHARMACODYNAMICS; PHARMACOGENOMICS; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR OCCUPANCY; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SKIN DISEASE; TACHYCARDIA; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSION; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MOOD DISORDERS; RECEPTORS, CELL SURFACE; SCHIZOPHRENIA;

EID: 77951091829     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.02.001     Document Type: Review

References (213)

1. Abbas A.I., Hedlund P.B., Huang X.P., Tran T.B., Meltzer H.Y., Roth B.L. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) 2009, 205:119-128.
2. Agid O., Kapur S., Remington G. Emerging drugs for schizophrenia. Expert Opin Emerg Drugs 2008, 13:479-495.
3. Albers L.J., Musenga A., Raggi M.A. Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?. Expert Opin Investig Drugs 2008, 17:61-75.
4. Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychaitric Assocation, APA, Washington DC. 4th ed.
5. Anderson I.M. Meta-analysis studies on new antidepressants. Br Med Bull 2001, 57:161-178.
6. Andreasen J.T., Olsen G.M., Wiborg O., Redrobe J.P. Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests. J Psychopharmacol 2009, 23:797-804.
7. Ardayfio P.A., Benvenga M.J., Chaney S.F., Love P.L., Catlow J., Swanson S.P., Marek G.J. The 5-hydroxytryptamine2A receptor antagonist R-(+)-alpha-(2, 3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) attenuates impulsivity after both drug-induced disruption (dizocilpine) and enhancement (antidepressant drugs) of differential-reinforcement-of-low-rate 72-s behavior in the rat. J Pharmacol Exp Ther 2008, 327:891-897.
8. Arnsten A.F. Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology 2004, 174:25-31.
9. Artigas F., Romero L., de Montigny C., Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996, 19:378-383.
10. Azorin J.M., Kaladjian A. An update on the treatment of bipolar depression. Expert Opin Pharmacother 2009, 10:161-172.
11. Bachmann R.F., Wang Y., Yuan P., Zhou R., Li X., Alesci S., Du J., Manji H.K. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int J Neuropsychopharmacol 2009, 19:1-18.
12. Bai F., Bergeron M., Nelson D.L. Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus. Neuropharmacology 2003, 44:1013-1021.
13. Baldessarini R.J. Treatment research in bipolar disorder: issues and recommendations. CNS Drugs 2002, 16:721-729.
14. Baldessarini R.J., Tarazi F.I. Pharmacotherapy of psychosis and mania. Goodman and Gilman's the pharmacological basis of therapeutics 2005, 461-500. McGraw-Hill, New York, NY. L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.).
15. Baldwin C.M., Scott L.J. Quetiapine extended release: in schizophrenia. CNS Drugs 2009, 23:261-269.
16. Ban T.A. The role of serendipity in drug discovery. Dialogues Clin Neurosci 2006, 8:335-344.
17. Bantick R.A., Deakin J.F., Grasby P.M. The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?. J Psychopharmacol 2001, 15:37-46.
18. Beaulieu J.M., Gainetdinov R.R., Caron M.G. Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 2009, 49:327-347.
19. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
20. Bian Q., Kato T., Monji A., Hashioka S., Mizoguchi Y., Horikawa H., Kanba S. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:42-48.
21. Binder E.B., Kinkead B., Owens M.J., Nemeroff C.B. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of APDs. Biol Psychiatry 2001, 50:856-872.
22. Binneman B., Feltner D., Kolluri S., Shi Y., Qiu R., Stiger T. A 6-week randomized, placebo-controlled trial of CP-316, 311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 2008, 165:617-620.
23. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95. Biomarkers Definitions Working Group.
24. Bishara D., Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 2008, 68:2269-2292.
25. Blier P. Optimal use of antidepressants: when to act?. J Psychiatry Neurosci 2009, 34:80.
26. Blier P., Gobbi G., Turcotte J.E., de Montigny C., Boucher N., Hébert C., Debonnel G. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009, 19:457-465.
27. Bobo W.V., Shelton R.C. Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data. Expert Opin Pharmacother 2009, 10:2145-2159.
28. Browne R.G. Effects of antidepressants and anticholinergics in a mouse "behavioral despair" test. Eur J Pharmacol 1979, 58:331-334.
29. Bymaster F.P., Felder C., Ahmed S., McKinzie D. Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Targets CNS Neurol Disord 2002, 1:163-181.
30. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., Morin S.M., Gehlert D.R., Perry K.W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mehanism for efficacy in attention deficit hyperactivity disorder. Neuropsychopharmacology 2002, 27:699-711.
31. Calabrese J.R., Muzina D.J., Kemp D.E., Sachs G.S., Frye M.A., Thompson T.R., Klingman D., Reed M.L., Hirschfeld R.M. Predictors of bipolar disorder risk among patients currently treated for major depression. MedGenMed 2006, 8.
32. Cannon T.D., Cadenhead K., Cornblatt B., Woods S.W., Addington J., Walker E., Seidman L.J., Perkins D., Tsuang M., McGlashan T., Heinssen R. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008, 65:28-37.
33. Carpenter W.T. Clinical constructs and therapeutic discovery. Schizophr Res 2004, 72:69-73.
34. Carpenter W.T., Buchanan R.W. Lessons to take home from CATIE. Psychiatr Serv 2008, 59:523-525.
35. Carpenter W.T., Koenig J.I. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 2008, 33:2061-2079.
36. Casey D.E., Zorn S.H. The pharmacology of weight gain with antipsychotics. J Clin Psychiatry 2001, 62:4-10.
37. Chau D.T., Rada P., Kosloff R.A., Taylor J.L., Hoebel B.G. Nucleus accumbens muscarinic receptors in the control of behavioral depression: antidepressant-like effects of local M1 antagonist in the Porsolt swim test. Neuroscience 2001, 104:791-798.
38. 4 receptor agonist. Psychopharmacology 2006, 188:244-251.
39. Chenard B.L., Menniti F.S. Antagonists selective for NMDA receptors containing the NR2B subunit. Curr Pharm Des 1999, 5:381-404.
40. Cipriani A., Furukawa T.A., Salanti G., Geddes J.R., Higgins J.P., Churchill R., Watanabe N., Nakagawa A., Omori I.M., McGuire H., Tansella M., Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009, 373:746-758.
41. Conn P.J., Roth B.L. Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacology 2008, 33:2048-2060.
42. Conn P.J., Tamminga C., Schoepp D.D., Lindsley C. Schizophrenia: moving beyond monoamine antagonists. Mol Interv 2008, 8:99-107.
43. Cryan J.F., Slattery D.A. Animal models of mood disorders: recent developments. Curr Opin Psychiatry 2007, 20:1-7.
44. Davis J.M., Chen N., Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003, 60:553-564.
45. De Paulis T. M-100907 (Aventis). Curr Opin Investig Drugs 2001, 2:123-132.
46. De Wied D., Sigling H.O. Neuropeptides involved in the pathophysiology of schizophrenia and major depression. Neurotox Res 2002, 4:453-468.
47. Dean B. The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice. J Neurochem 2003, 85:1-13.
48. Dean B., Scarr E. APDs: evolving mechanisms of action with improved therapeutic benefits. Curr Drug Targets CNS Neurol Disord 2004, 3:217-225.
49. Dean B., Bymaster F.P., Scarr E. Muscarinic receptors in schizophrenia. Curr Mol Med 2003, 3:419-426.
50. Delgado P.L., Michaels T. Reboxetine: a review of efficacy and tolerability. Drugs Today (Barc) 1999, 35:725-737.
51. Di Matteo V., Cacchio M., Di Giulio C., Esposito E. Role of serotonin(2C) receptors in the control of brain dopaminergic function. Pharmacol Biochem Behav 2002, 71:727-734.
52. DiazGranados N., Zarate C.A. A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder. Curr Psychiatry Rep. 2008, 10:510-519.
53. Dimova A. The range of therapeutic efficacy of atypical antipsychotics: a critical evaluation. Med Hypotheses 2003, 61:259-264.
54. Dremencov E., El Mansari M., Blier P. Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology 2007, 194:63-72.
55. Drevets W.C., Price J.L., Furey M.L. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008, 213:93-118.
56. Dubertret C., Hanoun N., Ades J., Hamon M., Gorwood P. Family-based association study of the serotonin-6 receptor gene (C267T polymorphism) in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004, 126:10-15.
57. Duman R.S. Depression: a case of neuronal life and death?. Biol Psychiatry 2004, 56:140-145.
58. Dunlop B.W., Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007, 64:327-337.
59. Eli Lilly and Company. Lilly announces inconclusive phase II study results for mGlu2/3 at the International Congress on Schizophrenia Research. Press release, March 29, 2009.
60. Enomoto T., Ishibashi T., Tokuda K., Ishiyama T., Toma S., Ito A. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res 2008, 186:197-207.
61. Ertugrul A., Meltzer H.Y. Antipsychotic drugs in bipolar disorder. Int J Neuropsychopharmacol 2003, 6:277-284.
62. Fell M.J., Svensson K.A., Johnson B.G., Schoepp D.D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R, 4S, 5S, 6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4, 6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 2008, 326:209-217.
63. 2 receptors by the mGlu2/3 receptor agonists LY354740 and LY379268. J Pharmacol Exp Ther 2009, 331:1126-1136.
64. 1A receptor antagonist, WAY-100635. Eur J Pharm 1995, 281:81-88.
65. Freedman R., Goldowitz D. Studies on the hippocampal formation: from basic development to clinical applications: studies on schizophrenia. Prog Neurobiol 2010, 90:263-275.
66. Freedman R., Olincy A., Buchanan R.W., Harris J.G., Gold J.M., Johnson L., Allensworth D., Guzman-Bonilla A., Clement B., Ball M.P., Kutnick J., Pender V., Martin L.F., Stevens K.E., Wagner B.D., Zerbe G.O., Soti F., Kem W.R. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008, 165:1040-1047.
67. Fujita Y., Ishima T., Kunitachi S., Hagiwara H., Zhang L., Iyo M., Hashimoto K. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:336-339.
68. Fuller R.W., Wong D.T., Robertson D.W. Fluoxetine, a selective inhibitor of serotonin uptake. Med Res Rev 1991, 11:17-34.
69. Furey M.L., Drevets W.C. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 2006, 63:1121-1129.
70. Garcia L.S., Comim C.M., Valvassori S.S., Réus G.Z., Stertz L., Kapczinski F., Gavioli E.C., Quevedo J. Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:450-455.
71. Garnier J.-P. Rebuilding the R&D engine in big pharma. Harv Bus Rev May 2008, 1-9.
72. Gaynes B.N., Rush A.J., Trvedi M.H., Wisniewski S.R., Spencer D., Fava M. The STAR*D study: treating depression in the real world. Cleve Clin J Med 2008, 75:57-66.
73. Geyer M.A. Developing translational animal models for symptoms of schizophrenia or bipolar mania. Neurotox Res 2008, 14:71-78.
74. Goodnick P.J. Bipolar depression: a review of randomised clinical trials. Expert Opin Pharmacother 2007, 8:13-21.
75. Gray J.A., Roth B.L. The pipeline and future of drug development in schizophrenia. Mol Psychiatry 2007, 12:904-922.
76. Hajós M., Fleishaker J.C., Filipiak-Reisner J.K., Brown M.T., Wong E.H.F. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 2004, 10:23-44.
77. Haldane M., Cunningham G., Androutsos C., Frangou S. Structural brain correlates of response inhibition in bipolar disorder I. J Psychopharmacol 2008, 22:138-143.
78. Hashimoto K. Microglial activation in schizophrenia and minocycline treatment. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1758-1759.
79. Hendrie C. The funding crisis in psychopharmacology: an historical perspective. J Psychopharmacol 2008, Dec 12.
80. Hendrie C.A., Pickles A.R. Depression as an evolutionary adaptation: implications for the development of preclinical models. Med Hypotheses 2009, 72:342-347.
81. Herpfer I., Lieb K. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 2005, 19:275-293.
82. Hirschfeld R.M. Antidepresants in long-term therapy: review of tricyclic antdepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000, 403:35-38.
83. Hirschfeld R.M. Are depression and bipolar disorder the same illness?. Am J Psychiatry 2005, 162:1241-1242.
84. Hirschfeld R.M. Screening for bipolar disorder. Am J Manag Care 2007, 13(7 Suppl):S164-S169.
85. Hou Y., Wu C.F., Yang J.Y., He X., Bi X.L., Yu L., Guo T. Effects of clozapine, olanzapine and haloperidol on nitric oxide production by lipopolysaccharide-activated N9 cells. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1523-1528.
86. Jarskog L.F., Miyamoto S., Lieberman J.A. Schizophrenia: new pathological insights and therapies. Annu Rev Med 2007, 58:49-61.
87. 1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008, 33:2303-2312.
88. 2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:1081-1090.
89. 2+ regulation in vitro. J Neurochem 2008, 106:815-825.
90. Kessler R.C., Gruber M., Hettema J.M., Hwang I., Sampson N., Yonkers K.A. Co-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up. Psychol Med 2008, 38:365-374.
91. Kind P., Sorensen J. The cost of depression. Int Clin Psychopharmacol 1993, 7:191-195.
92. 1 receptors. Psychopharmacology 2009, 207:119-125.
93. Kola I. The state of innovation in drug development. Clin Pharmacol Ther 2008, 83:227-230.
94. Kola I., Hazuda D. Innovation and greater probability of success in drug discovery and development - from target to biomarkers. Curr Opin Biotechnol 2005, 16:644-646.
95. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 2004, 3:711-715.
96. Kupfer D.J., Donaldson C., Brown Y., Malliaris Y. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002, 63:120-125.
97. Lam D., Frank E., Grochocinski V., Cluss P., Houck P., Staph D. Burden and marital and sexual satisfaction in the partners of bipolar patients. Bipolar Disord 2005, 7:431-440.
98. Lee C.M., Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci 2006, 27:310-316.
99. Levin Y., Wang L., Schwarz E., Koethe D., Leweke F.M., Bahn S. Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Mol Psychiatry 2009, Jun 23, (Electronic publication ahead of print).
100. Levkovitz Y., Levi U., Braw Y., Cohen H. Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res 2007, 18:154-162.
101. Li X., Tizzano J.P., Griffey K., Clay M., Lindstrom T., Skolnick P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 2001, 40:1028-1033.
102. Li Z., Huang M., Ichikawa J., Dai J., Meltzer H.Y. N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M(1) muscarinic receptors. Neuropsychopharmacology 2005, 30:1986-1995.
103. Liang Y., Shaw A.M., Boules M., Briody S., Robinson J., Oliveros A., Blazar E., Williams K., Zhang Y., Carlier P.R., Richelson E. Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S, 2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS). J Pharmacol Exp Ther 2008, 327:573-583.
104. Lieberman J.A. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry 2007, 68(2):e04.
105. Lippiello P.M., Beaver J.S., Gatto G.J., James J.W., Jordan K.G., Traina V.M., Xie J., Bencherif M. TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity. CNS Neurosci Ther 2008, 14:266-277.
106. 2A serotonin receptors selectively in primate brain. Neuropharmacology 1998, 37:1147-1158.
107. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., Manji H.K. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008, 63:349-352.
108. Mailman R.B. GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 2007, 28:390-396.
109. Marek G., Merchant K. Developing therapeutics for schizophrenia and other psychotic disorders. NeuroRx 2005, 2:579-589.
110. Markou A., Chiamulera C., Geyer M.A., Tricklebank M., Steckler T. Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology 2009, 34:74-89.
111. Martin L.F., Kem W.R., Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology 2004, 174:54-64.
112. Mathew S.J., Murrough J.W., Aan Het Rot M., Collins K.A., Reich D.L., Charney D.S. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 2009, 17:1-12.
113. Maziade M., Roy M.-A., Chagnon Y., Clinhe D., Fournier J., Montgrain N., Dion C., Lavallee J., Garneau Y., Gingras N., Nicole L., Pires A., Ponton A., Potvin A., Wallot H., Merette C. Shared and specific susceptibility loci for schizophrenia and bipolar disorder: a dense genome scan in Eastern Quebec families. Mol Psychiatry 2005, 10:486-499.
114. McGorry P.D., Nelson B., Amminger G.P., Bechdolf A., Francey S.M., Berger G., Riecher-Rössler A., Klosterkötter J., Ruhrmann S., Schultze-Lutter F., Nordentoft M., Hickie I., McGuire P., Berk M., Chen E.Y., Keshavan M.S., Yung A.R. Intervention in individuals at ultra high risk for psychosis: a review and future directions. J Clin Psychiatry 2009, 70:1206-1212.
115. McIntyre R.S., Soczynska J.K., Woldeyohannes H.O., Alsuwaidan M., Konarski J.Z. A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 2007, 8:1211-1219.
116. Meltzer H.Y., Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 2008, 172:177-197.
117. Mendoza M.C., Lindenmayer J.P. N-desmethylclozapine: is there evidence for its antipsychotic potential?. Clin Neuropharmacol 2009, 32:154-157.
118. Merikangas K.R., Akiskal H.S., Angst J., Greenberg P.E., Hirschfeld R.M., Petukhova M., Kessler R.C. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007, 64:543-552.
119. Meyer J.M., Loebel A.D., Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 2009, 18:1715-1726.
120. Millan M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006, 110:135-370.
121. Millan M.J. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 2009, 6:53-77.
122. Mirza N.R., Peters D., Sparks R.G. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev 2003, 9:159-186.
123. Miyaoka T. Clinical potential of minocycline for schizophrenia. CNS Neurol Disord Drug Targets 2008, 7:376-381.
124. Miyaoka T., Yasukawa R., Yasuda H., Hayashida M., Inagaki T., Horiguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:304-307.
125. Miyaoka T., Yasukawa R., Yasuda H., Hayashida M., Inagaki T., Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol 2008, 31:287-292.
126. Mizoguchi H., Takuma K., Fukakusa A., Ito Y., Nakatani A., Ibi D., Kim H.C., Yamada K. Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice. Psychopharmacology 2008, 196:233-241.
127. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 2003, 40:881-884.
128. Möller H.J. Systematic of psychiatric disorders between categorical and dimensional approaches: Kraepelin's dichotomy and beyond. Eur Arch Psychiatry Clin Neurosci 2008, 258(Suppl 2):48-73.
129. Morphy R., Kay C., Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today 2004, 9:641-651.
130. Nakamura M., Ogasa M., Guarino J., Phillips D., Severs J., Cucchiaro J., Loebel A. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009, 70:829-836.
131. Nebert D.W., Jorge-Nebert, Vesell E.S. Pharmacogenomics and "individualized drug therapy", high expectations, disappointing achievements. Am J Pharmacol 2003, 3:361-370.
132. Newcomer J.W. Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses. J Clin Psychiatry 2009, 70(Suppl 3):30-36.
133. Nussbaum A., Stroup T.S. Paliperidone for schizophrenia. Cochrane Database Syst Rev 2008, Apr, 16(2):CD006369.
134. Nyberg S., Takano A., Karlsson P., McCarthy D., Lee Chi-Ming, Mathe A.A., Halldin C., Farde L. PET measured occupancy of the norepinephrine transporter by extended release quetiapine fumarate (quetiapine XR) in brain of healthy subjects. ACNP Annual Congress 2007, 127.
135. 2A, and NET occupancy by quetiapine and norquetiapine in non-human primate. SOBP Annual Congress 2008, 58.
136. Overstreet D.H., Janowsky D.S., Gillin J.C., Shiromani P.J., Sutin E.L. Stress-induced immobility in rats with cholinergic supersensitivity. Biol Psychiatry 1986, 21:657-664.
137. Pani L., Marchese G. Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. Expert Opin Drug Deliv 2009, 6:319-331.
138. Papakostas G.I., Thase M.E., Fava M., Nelson J.C., Shelton R.C. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007, 62:1217-1227.
139. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., Schoepp D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007, 13:1102-1107.
140. Perlis R.H., Brown E., Baker R.W., Nierenberg A.A. Clinical features of bipolar depression versus major depressive disorder in large multicenter trials. Am J Psychiatry 2006, 163:225-231.
141. Popik P., Kos T., Sowa-Kućma M., Nowak G. Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacology 2008, 198:421-430.
142. Preskorn S.H. How multiple medication use evolves and the importance of therapeutic trials: the slippery slide. J Psychiatr Pract 2008, 14:170-175.
143. Preskorn S.H., Lacey R.L. Polypharmacy: when is it rational?. J Psychiatr Pract 2007, 13:97-105.
144. Preskorn S.H., Baker B., Kolluri S., Menniti F.S., Krams M., Landen J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101, 606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008, 28:631-637.
145. Reynolds G.P., Kirk S.L. Metabolic side effects of antipsychotic drug - pharmacological mechanisms. Pharmacol Ther 2010, 125:169-179.
146. Reynolds G.P., Abdul-Monim Z., Neill J.C., Zhang Z.J. Calcium binding protein markers of GABA deficits in schizophrenia - postmortem studies and animal models. Neurotox Res 2004, 6:57-61.
147. Reynolds G.P., Hill M.J., Kirk S.L. The 5-HT2C receptor and antipsychotic induced weight gain - mechanisms and genetics. J Psychopharmacol 2006, 20(Suppl 4):15-18.
148. Richelson E. The clinical relevance of antidepressant interaction with neurotransmitter transporters and receptors. Psychopharmacol Bull 2002, 36:133-150.
149. Richelson E., Nelson A. Antagonism by antidepressants of neurotransmitter receptor in normal human brain in vitro. J Pharm Exp Ther 1984, 230:94-102.
150. Richelson E., Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000, 68:29-39.
151. Rickels K., Athanasiou M., Robinson D.S., Gibertini M., Whalen H., Reed C.R. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009, 70:326-333.
152. Rosse R.B., Schwartz B.L., Weizman A., Chilton M., Arnold D.S., Mastropaolo J. Therapeutic implications of a selective alpha7 nicotinic receptor abnormality in schizophrenia. Isr J Psychiatry Relat Sci 2005, 42:33-44.
153. Roth B.L. Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled?. Dialogues Clin Neurosci 2006, 8:303-309.
154. Roth B.L., Sheffler D.J., Kroeze W.K. Magic shotgun versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004, 3:353-359.
155. Rupniak N.M., Kramer M.S. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci 1999, 20:485-490.
156. Sacchetti E., Galluzzo A., Valsecchi P., Romeo F., Gorini B., Warrington L. MOZART study group. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizo Res 2009, 113:112-121.
157. Sajatovic M., Calabrese J.R., Mullen J. Quetiapine for the treatment of bipolar mania in older adults. Bipolar Disord 2008, 10:662-671.
158. Schatzberg A.F., Lindley S. Glucocorticoid antagonists in neuropsychiatric disorders. Eur J Pharmacol 2008, 583:358-364.
159. Schloesser R.J., Huang J., Klein P.S., Manji H.K. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008, 33:110-133.
160. Schmid E.F., Smith D.A. Is declining innovation in the pharmaceutical industry a myth?. Drug Discov Today 2005, 10:1031-1039.
161. Schmidt A.W., Lebel L.A., Howard H.R., Zorn S.H. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001, 425:197-201.
162. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996, 124:57-73.
163. Schrattenholz A., Soskić V. What does systems biology mean for drug development?. Curr Med Chem 2008, 15:1520-1528.
164. Schulz D.W., Mansbach R.S., Sprouse J., Braselton J.P., Collins J., Corman M., Dunaiskis A., Faraci S., Schmidt A.W., Seeger T., Seymour P., Tingley F.D., Winston E.N., Chen Y.L., Heym J. CP-154, 526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. PNAS 1996, 93:10477-10482.
165. 2 basis for schizophrenia. Synapse 2008, 62:819-828.
166. Selent J., Bauer-Mehren A., Lopez L., Loza M.I., Sanz F., Pastor M. A novel multilevel statistical method for the study of the relationships between multireceptorial binding affinity profiles and in vivo endpoints. Mol Pharmacol 2009, 77:149-158.
167. Settle E.C. Antidepressant drugs: disturbing and potentially dangerous adverse effects. J Clin Psychiatry 1998, 59(Suppl 16):25-30.
168. Shahid M., Walker G.B., Zorn S.H., Wong E.H. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009, 23:65-73.
169. Shajahan P., Taylor M. The uses and outcomes of quetiapine in depressive and bipolar mood disorders in clinical practice. J Psychopharmacol 2009, (Electronic publication ahead of print).
170. Shannon H.E., Rasmussen K., Bymaster F.P., Hart J.C., Peters S.C., Swedberg M.D., Jeppesen L., Sheardown M.J., Sauerberg P., Fink-Jensen A. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizo Res 2000, 42:249-259.
171. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003, 28:1400-1411.
172. Shekhar A., Potter W.Z., Lightfoot J., Lienemann J., Dubé S., Mallinckrodt C., Bymaster F.P., McKinzie D.L., Felder C.C. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 2008, 165:1033-1039.
173. Skolnick P., Popik P., Trullas R. Glutamate-based antidepressants: 20years on. Trends Pharmacol Sci 2009, 30:563-569.
174. Snigdha S., Thumbi C., Reynolds G.P., Neill J.C. Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats. J Psychopharmacol 2008, 22:567-571.
175. Sodhi M., Wood K.H., Meador-Woodruff J. Role of glutamate in schizophrenia: integrating excitatory avenues of research. Expert Rev Neurother 2008, 8:1389-1406.
176. Stahl S.M. Multifunctional drugs: a novel concept for psychopharmacology. CNS Spectrums 2009, 14:71-73.
177. Stanhope K.J., Mirza N.R., Bickerdike M.J., Bright J.L., Harrington N.R., Hesselink M.B., Kennett G.A., Lightowler S., Sheardown M.J., Syed R., Upton R.L., Wadsworth G., Weiss S.M., Wyatt A. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther 2001, 299:782-792.
178. Strakowski S.M., Adler C.M., Holland S.K., Mills N.P., DelBello M.P., Eliassen J.C. Abnormal FMRI brain activation in euthymic bipolar disorder patients during a counting Stroop interference task. Am J Psychiatry 2005, 162:1697-1705.
179. Swartz M.S., Stroup T.S., McEvoy J.P., Davis S.M., Rosenheck R.A., Keefe R.S., Hsiao J.K., Lieberman J.A. What CATIE found: results from the schizophrenia trial. Psychiatr Serv 2008, 59:500-506.
180. Tarazi F.I., Florijn W.J., Creese I. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology 1996, 128:371-379.
181. 4-like dopamine receptors. Neuropsychopharmacology 1997, 17:186-196.
182. Tarazi F.I., Zhang K., Baldessarini R.J. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2001, 297:711-717.
183. Tarazi F.I., Zhang K., Baldessarini R.J. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology 2002, 161:263270.
184. Tarazi F.I., Baldessarini R.J., Kula N.S., Zhang K. Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2003, 306:1145-1151.
185. 2C serotonin receptors. Nature 1995, 374:542-546.
186. Trivedi M.H., Fava M., Wisniewski S.R., Thase M.E., Quitkin F., Warden D., Ritz L., Nierenberg A.A., Lebowitz B.D., Biggs M.M., Luther J.F., Shores-Wilson K., Rush A.J. STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006, 354:1243-1252.
187. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., Shores-Wilson K., Biggs M.M., Balasubramani G.K., Fava M. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40.
188. Trivedi M.H., Hollander E., Nutt D., Blier P. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J Clin Psychiatry 2008, 69:246-258.
189. Trivedi M.H., Desaiah D., Ossanna M.J., Pritchett Y.L., Brannan S.K., Detke M.J. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol 2008, 23:161-169.
190. Trivedi M.H., Thase M.E., Osuntokun O., Henley D.B., Case M., Watson S.B., Campbell G.M., Corya S.A. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry 2009, 70:387-396.
191. Uslaner J.M., Smith S.M., Huszar S.L., Pachmerhiwala R., Hinchliffe R.M., Vardigan J.D., Hutson P.H. Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants. Psychopharmacology 2009, 206:641-651.
192. van Os J., Kapur S. Schizophrenia. Lancet 2009, 374:635-645.
193. Vornik L.A., Hirschfeld R.M. Bipolar disorder: quality of life and the impact of atypical antipsychotics. Am J Manag Care 2005, 11(9 Suppl):S275-S280.
194. Weber J., McCormack P.L. Asenapine. CNS Drugs 2009, 23:781-792.
195. Wehr T.A., Goodwin F.K. Can antidepressants cause mania and worsen the course of affective illness?. Am J Psychiatry 1987, 144:1403-1411.
196. Weisler R., Joyce J.M., McGill L., Lazarus Szamos J., Eriksson H. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 2009, 14:299-313.
197. Westenberg H.G.M. Pharmacology of antidepressants: selectivity or multiplicity. J Clin Psychiatry 1999, 60(suppl 9):34-41.
198. Willner P., Hale A.S., Argyropoulos S. Dopaminergic mechanism of antidepressant action in depressed patients. J Affect Disord 2005, 86:37-45.
199. Wingo A.P., Harvey P.D., Baldessarini R.J. Neurocognitive impairment in bipolar disorder patientsfunctional implications. Bipolar Disord 2009, 11:113-125.
200. Winter H.R., Earley W.R., Hamer-Maansson J.E., Davis P.C., Smith M.A. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adolesc Psychopharmacol 2008, 18:81-98.
201. Wong E.H.F., Kemp J.A., Priestley T., Knight A.R., Woodruff G.N., Iversen L.L. The anticonvulsant MK-801 is a potent N-methyl-d-aspartate antagonist. Proc Natl Acad Sci USA 1986, 83:7104-7108.
202. Wong E.H.F., Sonders M.S., Amara S.G., Tinholt P.M., Piercey M.F., Hoffmann W.P., Hyslop D.K., Franklin S., Porsolt R.D., Bonsignori A., Carfagna N., McArthur R.A. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 2000, 47:818-829.
203. Wong E.H.F., Nikam S.S., Shahid M. Multi- and single-target agents for major psychiatric diseases: therapeutic opportunities and challenges. Curr Opin Investig Drugs 2008, 9:28-36.
204. Wood M.D., Scott C., Clarke K., Cato K.J., Patel N., Heath J., Worby A., Gordon L., Campbell L., Riley G., Davies C.H., Gribble A., Jones D.N. Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets 2006, 5:445-452.
205. Woolley M.L., Carter H.J., Gartlon J.E., Watson J.M., Dawson L.A. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice. Eur J Pharmacol 2009, 603:147-149.
206. Yatham L.N., Kennedy S.H., Schaffer A., Parikh S.V., Beaulieu S., O'Donovan C., MacQueen G., McIntyre R.S., Sharma V., Ravindran A., Young L.T., Young A.H., Alda M., Milev R., Vieta E., Calabrese J.R., Berk M., Ha K., Kapczinski F. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009, 11:225-255.
207. Youdim M.B.H., Buccadfasco J.J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 2005, 26:27-35.
208. Young J.W., Powell S.B., Risbrough V., Marston H.M., Geyer M.A. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 2009, 122(2):150-202.
209. Zarate C.A., Manji H.K. Bipolar disorder: candidate drug targets. Mt Sinai J Med 2008, 75:226-247.
210. Zarate C.A., Manji H.K. Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs 2009, 3:569-582.
211. Zarate C.A., Singh J., Manji H.K. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 2006, 59:1006-1020.
212. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D.S., Manji H.K. Robust, rapid and relatively sustained antidepressant effects with a single-dose of an NMDA antagonist in treatment-resistant major depression: a double-blind placebo controlled study. Arch Gen Psychiatry 2006, 63:856-863.
213. Zhang L., Shirayama Y., Iyo M., Hashimoto K. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 2007, 32:2004-2010.